Galmed Pharmaceuticals Ltd. carries no debt; cash flow comfortably covers obligations.

Galmed Pharmaceuticals Ltd.'s free cash flow has decreased 7.40% from $-5.88M last year to $-6.32M, signaling decreasing performance

Galmed Pharmaceuticals Ltd.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Galmed Pharmaceuticals Ltd. has insufficient data to evaluate this check.

Galmed Pharmaceuticals Ltd. has a net cash position, so leverage is healthy.

Galmed Pharmaceuticals Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.

Galmed Pharmaceuticals Ltd. has insufficient data to evaluate this check.

Galmed Pharmaceuticals Ltd.'s short-term assets of $18.63M exceed its short-term liabilities of $2.85M

Galmed Pharmaceuticals Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Galmed Pharmaceuticals Ltd.'s return on equity of -64.10%, is lower than 15.00%, indicating bad performance

Galmed Pharmaceuticals Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Galmed Pharmaceuticals Ltd. had positive net income in only 0 out of 5 years, indicating unstable earnings

Galmed Pharmaceuticals Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it

Galmed Pharmaceuticals Ltd. has negative free cash flow, indicating cash burn

Galmed Pharmaceuticals Ltd.'s yearly earnings has decreased 37.14% since last year from $-7.52M to $-10.31M, signaling decreasing performance

Galmed Pharmaceuticals Ltd.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -66.60% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Galmed Pharmaceuticals Ltd. has insufficient revenue history to calculate 3-year revenue CAGR.

Galmed Pharmaceuticals Ltd. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Galmed Pharmaceuticals Ltd. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Galmed Pharmaceuticals Ltd. has insufficient data to evaluate this check.

Galmed Pharmaceuticals Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Galmed Pharmaceuticals Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Galmed Pharmaceuticals Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Galmed Pharmaceuticals Ltd. has insufficient data to evaluate this check.

Galmed Pharmaceuticals Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Galmed Pharmaceuticals Ltd. has a price-to-book ratio of 0.28x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Galmed Pharmaceuticals Ltd. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue